In US District Court on 31 August 2017
Dr Reddys Laboratories announced that on 31 August 2017, the United States District Court, for the District of Delaware, issued its judgement in favour of Dr Reddys Laboratories, ruling that the proposed generic version of Suboxone (buprenorphine and naloxone) sublingual film does not infringe U.S. Patent Nos. 8,017,150; 8,603,514 and 8,900,497 as asserted by Indivior.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
